Capricor Positive 3-Year Efficacy Results from Open Label Extension Study in Duchenne

 --Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)--

--Stabilization in Left Ventricular Ejection Fraction (LVEF) Suggests Preservation of Cardiac Function--

--Results Recently Shared with FDA at Type-B Meeting Held in May 2024--

https://www.biospace.com/article/releases/capricor-therapeutics-announces-positive-3-year-efficacy-results-from-hope-2-open-label-extension-study-of-cap-1002-in-duchenne-muscular-dystrophy/